Agenus (AGEN) Stock Price, News & Analysis

Company Overview

Agenus, Inc. (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform. Its adjuvant portfolio features QS-21 Stimulon, an immunostimulatory component used to bolster vaccine efficacy. Through strategic collaborations and licensing agreements with leading pharmaceutical companies, the firm has advanced multiple programs into late-stage clinical trials, focusing on refractory and treatment-resistant cancer indications.

Founded in 1994 as Antigenics and rebranded as Agenus in 2016, the company operates research and development activities in the United States and Europe. In 2015, it completed the spin-out of NewLink Genetics, enabling a streamlined focus on its oncology-centric assets. Over the years, Agenus has expanded its scientific platform through targeted acquisitions and partnerships, reinforcing its commitment to innovative immunotherapeutic strategies.

Under the leadership of founder and Chief Executive Officer Garo Armen, Agenus continues to build on its legacy of immuno-oncology innovation. The company is dedicated to translating its platform technologies into combination therapies that address unmet needs in cancer treatment, with the goal of delivering durable responses and improving patient outcomes worldwide.

Key Stats

• Today's Range: $4.47 to $4.73
• 50-Day Range: $4.16 to $7.06
• 52-Week Range: $1.38 to $7.34
• Volume: 314,771 shs
• Average Volume: 789,528 shs
• Market Capitalization: $143.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Moderate Buy

Agenus Stock Analysis - MarketRank™

Agenus scored higher than 82% of companies evaluated by MarketBeat, and ranked 200th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Agenus has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Agenus has a consensus price target of $14.50, representing about 221.2% upside from its current price of $4.52.

Amount of Analyst Coverage

Agenus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Agenus are expected to grow in the coming year, from ($12.55) to ($7.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agenus is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agenus is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.10% of the float of Agenus has been sold short.

Short Interest Ratio / Days to Cover

Agenus has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Agenus has recently increased by 6.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agenus does not currently pay a dividend.

Dividend Growth

Agenus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.93

Percentage of Shares Shorted

9.10% of the float of Agenus has been sold short.

Short Interest Ratio / Days to Cover

Agenus has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Agenus has recently increased by 6.30%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.42

News Sentiment

Agenus has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Agenus this week, compared to 6 articles on an average week.

Search Interest

10 people have searched for AGEN on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.

MarketBeat Follows

5 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Agenus insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Agenus is held by insiders.

Percentage Held by Institutions

61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AGEN Stock Analysis - Frequently Asked Questions

How have AGEN shares performed this year?

Agenus' stock was trading at $2.74 at the beginning of 2025. Since then, AGEN stock has increased by 64.8% and is now trading at $4.5150.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) issued its quarterly earnings results on Monday, August, 11th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by $0.22. The biotechnology company had revenue of $25.70 million for the quarter, compared to the consensus estimate of $49.71 million.
Read the conference call transcript.

When did Agenus' stock split?

Shares of Agenus reverse split on Friday, April 12th 2024.The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Agenus' major shareholders?

Agenus' top institutional investors include Marshall Wace LLP (1.58%), Bank of America Corp DE (1.32%), Geode Capital Management LLC (1.16%) and Walleye Capital LLC (0.72%). Insiders that own company stock include Agenus Inc and Garo H Armen.
View institutional ownership trends.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Agenus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agenus investors own include DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/12/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AGEN
• CIK: 1098972
• Web: agenusbio.com
• Phone: (781) 674-4400
• Fax: 781-674-4200
• Employees: 440
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Agenus: $14.50
• High Price Target: $23.00
• Low Price Target: $6.00
• Potential Upside/Downside: +205.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$227.21 million
• Net Margins: -167.52%
• Pretax Margin: -167.53%
• Return on Equity: N/A
• Return on Assets: -81.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $101.71 million
• Price / Sales: 1.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($13.06) per share
• Price / Book: -0.36

Miscellaneous

• Outstanding Shares: 31,864,000
• Free Float: 30,111,000
• Market Cap: $151.04 million
• Optionable: Optionable
• Beta: 1.44